BioVinc is a pre-clinical biopharma focused on drug development to treat bone infections – specifically prosthetic joint infection (PJI). Currently, there is no effective treatment for patients with PJI despite a 0K+ price tag – the most common option is amputation with a 5 yr. survival window.

BioVinc delivers antibiotics deep into bone surrounding the implant and needed a new website to tell their story to potential partners to help fund preclinical studies and clinical trials.

The new website explains how BioVinc’s breakthrough technology meets an unmet medical need far better than the current standard of care.